BlackRock, Inc. 13D and 13G filings for Ligand Pharmaceuticals Incorporated:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-05 1:23 pm Sale | 2024-12-31 | 13G | Ligand Pharmaceuticals Incorporated LGND | BlackRock Inc. BLK | 2,945,939 15.600% | -16,155 (-0.55%) | Filing |
| 2024-01-22 2:03 pm Purchase | 2023-12-31 | 13G | Ligand Pharmaceuticals Incorporated LGND | BlackRock Inc. BLK | 2,962,094 17.000% | 172,615 (+6.19%) | Filing |
| 2023-01-26 08:52 am Unchanged | 2022-12-31 | 13G | Ligand Pharmaceuticals Incorporated LGND | BlackRock Inc. BLK | 2,789,479 16.500% | 0 (Unchanged) | Filing |
| 2023-01-20 5:17 pm Sale | 2022-12-31 | 13G | Ligand Pharmaceuticals Incorporated LGND | BlackRock Inc. BLK | 2,789,479 16.500% | -1,607,242 (-36.56%) | Filing |
| 2022-01-27 11:00 am Unchanged | 2021-12-31 | 13G | Ligand Pharmaceuticals Incorporated LGND | BlackRock Inc. BLK | 4,396,721 16.400% | 0 (Unchanged) | Filing |
| 2022-01-25 3:03 pm Purchase | 2021-12-31 | 13G | Ligand Pharmaceuticals Incorporated LGND | BlackRock Inc. BLK | 4,396,721 16.400% | 1,245,230 (+39.51%) | Filing |
| 2021-01-26 6:52 pm Sale | 2020-12-31 | 13G | Ligand Pharmaceuticals Incorporated LGND | BlackRock Inc. BLK | 3,151,492 12.200% | -671,917 (-17.57%) | Filing |